ReviewOncoTargets and therapy2025
Diagnosis and Management of Colorectal Cancer in the Gulf Area: Current Practice and Future Suggestions from Expert Opinions.
Review in OncoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Colorectal cancer incidence in Saudi Arabia, 2002-2023: Age-specific trends and implications for screening and prevention.Preventive medicine reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most diagnosed cancers, leading to considerable cancer-related deaths globally. Recently, a notable increase has been observed in annual CRC incidence rates, particularly among individuals aged ≤50 years. Rapid urbanization and lifestyle changes have contributed to this trend. Early diagnosis through structured screening programs remains crucial for improving prognosis, yet uptake in the Gulf remains suboptimal due to limited public awareness and gaps in the national screening infrastructure. Diagnostic approaches in the region increasingly incorporate advanced imaging modalities and molecular testing, although access to in-house testing facilities is limited, often resulting in delays in personalized therapy initiation. Treatment strategies for CRC in the Gulf are guided by international guidelines, and are tailored according to tumor characteristics, molecular profile, and patient status. Multidisciplinary teams in tertiary centers facilitate evidence-based management, while ongoing efforts aim to expand access to targeted therapies and optimize care pathways. Insufficient training, limited knowledge, and suboptimal communication between primary care providers and specialists have been identified. Also, limited in-house molecular testing often leads to outsourcing, causing delays in targeted therapy and higher treatment costs. In this perspective article, we provide an overview of current practices and propose future perspectives for the screening, diagnosis, and management of CRC in the Gulf region, with the aim of aiding clinicians in making informed decisions, enhancing patient care, and establishing the cornerstone for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.